Search Results - "Martin, G.P"

Refine Results
  1. 1

    Remotely monitored physical activity from older people with cardiac devices associates with physical functioning by Taylor, J K, Peek, N, Greenstein, A S, Sammut-Powell, C, Martin, G P, Ahmed, F Z

    Published in BMC geriatrics (17-06-2024)
    “…Accelerometer-derived physical activity (PA) from cardiac devices are available via remote monitoring platforms yet rarely reviewed in clinical practice. We…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    The 7SK/P-TEFb snRNP controls ultraviolet radiation-induced transcriptional reprogramming by Studniarek, Cécilia, Tellier, Michael, Martin, Pascal G.P., Murphy, Shona, Kiss, Tamás, Egloff, Sylvain

    Published in Cell reports (Cambridge) (13-04-2021)
    “…Conversion of promoter-proximally paused RNA polymerase II (RNAPII) into elongating polymerase by the positive transcription elongation factor b (P-TEFb) is a…”
    Get full text
    Journal Article
  5. 5

    A methodological approach for determining the effect of moisture content on the compaction properties of powders: Granular hydroxyapatite by Wade, J.B., Martin, G.P., Long, D.F.

    Published in Powder technology (01-09-2013)
    “…The effect of moisture on the compaction properties of hydroxyapatite (HA) was studied. A single lot of commercially available HA was heated at various…”
    Get full text
    Journal Article
  6. 6

    The influence of self-assembling supramolecular structures on the passive membrane transport of ion-paired molecules by Benaouda, F., Brown, M.B., Shah, B., Martin, G.P., Jones, S.A.

    Published in International journal of pharmaceutics (15-12-2012)
    “…The influence of solvent supramolecular structuring on the transmembrane transport rate (♦) and lag time to steady-state transport (♢) of diclofenac…”
    Get full text
    Journal Article
  7. 7

    Preparation and evaluation of the in vitro drug release properties and mucoadhesion of novel microspheres of hyaluronic acid and chitosan by Lim, S.T., Martin, G.P., Berry, D.J., Brown, M.B.

    Published in Journal of controlled release (15-05-2000)
    “…Rapid mucociliary clearance of intranasally administered drugs is often a key factor in determining the bioavailability of such therapeutic agents. The use of…”
    Get full text
    Journal Article
  8. 8

    Further characterization of a bacteriocin produced by Lactobacillus paracasei HL32 by Pangsomboon, K, Bansal, S, Martin, G.P, Suntinanalert, P, Kaewnopparat, S, Srichana, T

    Published in Journal of applied microbiology (01-06-2009)
    “…Purification, identification and partial characterization of bacteriocin produced by Lactobacillus paracasei HL32. It has been shown to have activity against…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro by Srichana, T., Martin, G.P., Marriott, C.

    “…It is a principal in the formulation of a dry powder aerosol that the device should enable a high fine particle fraction (FPF) of drug to be delivered to the…”
    Get full text
    Journal Article
  13. 13
  14. 14

    On the relationship between drug and carrier deposition from dry powder inhalers in vitro by Srichana, T, Martin, G.P, Marriott, C

    Published in International journal of pharmaceutics (01-06-1998)
    “…Dry powder inhaler formulations usually contain micronised drug particles and lactose as a carrier. Although the fine particle fraction (FPF) of drug from many…”
    Get full text
    Journal Article
  15. 15

    Impairment of adipose tissue in Prader–Willi syndrome rescued by growth hormone treatment by Cadoudal, T, Buléon, M, Sengenès, C, Diene, G, Desneulin, F, Molinas, C, Eddiry, S, Conte-Auriol, F, Daviaud, D, Martin, P G P, Bouloumié, A, Salles, J-P, Tauber, M, Valet, P

    Published in International Journal of Obesity (01-09-2014)
    “…Background: Prader–Willi syndrome (PWS) results from abnormalities in the genomic imprinting process leading to hypothalamic dysfunction with an alteration of…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Trends of sex differences in outcomes of cardiac electronic device implantations in the United States by Mohamed, M, Volgman, A.S, Contractor, T, Sharma, P.S, Kwok, C.S, Martin, G.P, Barker, D, Patwala, A, Mamas, M.A

    Published in European heart journal (01-11-2020)
    “…Abstract Background There is limited evidence on the differences in procedural outcomes between sexes after de novo cardiac implantable electronic device…”
    Get full text
    Journal Article
  18. 18

    The Association Between Socioeconomic Status, Sex, Race / Ethnicity and In-Hospital Mortality Among Patients Hospitalized for Heart Failure by Averbuch, T., Mohamed, M.O., Islam, S., Defilippis, E.M., Breathett, K., Alkhouli, M.A., Michos, E.D., Martin, G.P., Kontopantelis, E., Mamas, M.A., Van Spall, H.G.C.

    Published in Journal of cardiac failure (01-05-2022)
    “…•Among 4.3 million HF hospitalizations (5.1% deaths), low socioeconomic status (SES), male sex, and White race / ethnicity were independently associated with…”
    Get full text
    Journal Article
  19. 19

    Feasibility assessment for a novel reverse-phase wet granulation process: The effect of liquid saturation and binder liquid viscosity by Wade, J.B., Martin, G.P., Long, D.F.

    Published in International journal of pharmaceutics (20-11-2014)
    “…[Display omitted] A novel reverse-phase wet granulation process was developed and the feasibility of the process compared to a conventional wet granulation…”
    Get full text
    Journal Article
  20. 20

    Cytochrome P450 inhibition profile in liver of veal calves administered a combination of 17β-estradiol, clenbuterol, and dexamethasone for growth-promoting purposes by Cantiello, Michela, Carletti, Monica, Dacasto, Mauro, Martin, Pascal G.P., Pineau, Thierry, Capolongo, Francesca, Gardini, Giulia, Nebbia, Carlo

    Published in Food and chemical toxicology (01-08-2008)
    “…The effects of the administration of a combination of 17β-estradiol (10 mg i.m. for three times at 17 days intervals), dexamethasone (4 mg/day for 6 days and 5…”
    Get full text
    Journal Article